Even though it stays uncertain whether the kidney stone case was directly attributable to the rapid weightloss, scientific studies suggest that GLP-1 agonists—the class of medication retatrutide belongs to—could add to these risks. Another trial participant who shed 31% of their body weight had to regulate their diet regime, https://glowalluvi16802.alltdesign.com/retatrutide-pen-no-further-a-mystery-58054044